India’s market for continuous glucose monitoring (CGM) devices is expected to grow at around 5% a year between 2025 and 2035, according to new analysis from GlobalData. The rise reflects a broader shift towards real-time diabetes management as the country faces one of the world’s largest diabetes burdens.

GlobalData’s report on insulin pumps and CGM systems shows that India is projected to account for about 5% of the CGM market across the Asia-Pacific region in 2025. Analysts say growth is being supported by domestic innovation alongside demand from patients seeking alternatives to traditional blood glucose testing.

A recent development from the Indian Institute of Technology Madras (IIT-M) highlights this trend. Researchers at the institute’s Electronic Materials and Thin Films Lab have created a lower-cost, minimally invasive CGM device designed for local needs. The system uses reusable electronics paired with a disposable microneedle sensor patch to capture real-time glucose readings while aiming to keep the device comfortable and more affordable.

Shagufta Hasan, medical devices analyst at GlobalData, said: “India’s glucose monitoring landscape is shifting from innovation to impact. Affordable, homegrown CGM technologies are breaking long-standing barriers of cost and accessibility.” She added that these advances mark a step towards wider adoption and a more inclusive approach to diabetes care.

Despite strong momentum, challenges persist. Current CGM systems remain costly for many households, and the integration of monitoring devices with digital health platforms is uneven. Reimbursement structures also vary across the country, limiting uptake in some regions. GlobalData suggests that cost-efficient designs such as the IIT-M prototype could help close these gaps, particularly for rural and price-sensitive populations.

Hasan said: “As affordable, user-centric CGM devices gain traction in the local market, they are expected to significantly enhance diabetes care, reduce complications, and ease pressure on healthcare systems.” She noted that broader accessibility and continued innovation could position India as a growth engine for CGM adoption across the APAC region.

With diabetes rates continuing to rise, analysts expect India’s CGM market to play an increasingly important role in early intervention, long-term disease management and reducing the healthcare burden associated with poorly controlled glucose levels.